Creating antiseizure medications without the side effects

Unique approach in neurological drug development

NeuroPro Therapeutics developed analogs from drugs with a known safety profile that demonstrated potential to treat neurological conditions such as epilepsy, migraine, anxiety, and Alzheimer disease.

NeuroPro Therapeutics Logo


To engineer novel products that provide improved treatment solutions for patients suffering from neurological disorders such as epilepsy, migraine, anxiety, and Alzheimer disease.


Meet the team that is redefining neurological care

Daryl Hochman, PhD

Founder and President, NeuroPro Therapeutics, Inc. 

Dr. Daryl W. Hochman is an entrepreneur and neuroscientist with more than 20 years’ experience in the discovery and preclinical development of analogs for treating brain disorders. He is a leading expert in the pharmacology of NeuroPro’s drug candidates.

Daryl is the inventor of more than 30 issued and pending patents for drugs and medical devices, and the founder of two previous neurotherapeutic start-up companies. He has been a neuroscientist on the faculties of the University of Washington and Duke University Medical Center.


Lou Serafini Jr

President, CEO Fengate

Lou Serafini Jr joined Fengate in 1995 and became chief executive officer in 2002. During his tenure, Fengate has experienced tremendous growth by earning the trust of a growing group of institutional investors and securing more than $6.5 billion in capital under management.

With a commitment to provide top-tier client service, Lou has built a best-in-class team to work closely with Fengate’s valued investors and the firm’s industry partners. Lou oversees the executive management team and investor relations, and he is responsible for the overall vision for the firm and investment activities. Lou spearheads Fengate’s investment committees and sits on the board of the general partners for each fund.

Lu Cacioppo, CPA, FCPA

Managing Partner, Beringer Capital

Lu Cacioppo brings more than 35 years’ experience in helping entrepreneurs unlock value through expansion, acquisition, divestiture, refinancing, and strategic planning. His unparalleled insights into the unique issues facing company founders—particularly at the intersection of corporate and family ownership—have made him a trusted advisor to many of Canada’s most noteworthy private companies. He has also lent his expertise in corporate and personal taxation, mergers and acquisitions, and transaction due diligence to a broad cross-section of global clients spanning diverse industries.

Before joining Beringer, Lu spent a decade at Deloitte, where he was national managing partner of the firm’s Subject Matter Expert Program, and he also served as a leader of Deloitte Private. Before Deloitte, Lu was the managing partner of business consulting and accountancy firm HORNE LLP.



NeuroPro Therapeutics was originally funded by a group of angel investors. Since 2019, NeuroPro has been funded by a prominent equity fund that has committed its support to the development of NPT 2042.


Number of people around the world who have epilepsy.

3.4 Million:

Number of people in the United States who have epilepsy.

“There are more than 50 million individuals diagnosed with epilepsy worldwide. Of these, 30% to 40% are refractory to current therapies.” (WHO 2022)

Contact us to learn more about our growing company and NeuroPro investment opportunities.